FTC May Have Spilled Watson's Secrets, CEO Says

Law360, New York (August 10, 2010, 3:16 PM EDT) -- The CEO of Watson Pharmaceuticals Inc. has accused the Federal Trade Commission of concealing the extent of its attempts to broker a deal between Watson and Apotex Inc. to make a generic version of Cephalon Inc.'s narcolepsy drug Provigil, raising the possibility that it shared Watson's confidential information with Apotex.

Paul M. Bisaro said in a brief filed Monday in the U.S. District Court for the District of Columbia that the FTC, in response to his discovery requests, had revealed much more contact between the FTC...
To view the full article, register now.